Transplantation and Cellular Therapy 29(2023)222-227Transplantation andCellular TherapyASTCTAmerican Society forTransplantation and Cellular TherapyELSEVIERjournal homepage:www.astctjournal.orgGuide lineAmerican Society for Transplantation and Cellular Therapy Series,#6:Management of Invasive Candidiasis in Hematopoietic CellTransplantation RecipientsDionysios NeofytosWilliam J.Steinbach2,Kimberly Hanson3,Paul A.CarpenterGenovefa A.Papanicolaou,Monica A.SlavinDivision of Infectious Diseases,Transplant Infectious Disease Service,University Hospital of Geneva,Genev,Switzerland2 Department of Pediatrics College of Medicine,University ofArkansas for Medical Sciences Little Rock ArkansasTransplant Infectious Diseases and Immunocompromised Host Service,Clinical Microbiology.University of Utah,Salt Lake City,Utah4 Chinical Research Division,Fred Hutchinson Cancer Research Center,Seattle,Washington5 In fectious Diseases Service,Department ofMedicine,Memorial Sloan Kettering CancerCenter,New York New YorkDepartment of Inectious Disease Peter MacCallum Cancer Centre,Melboume,AustraliaArticle history:ABSTRACTReceived 7 January 2023The Practice Guidelines Committee of the American Society ofTransplantation and Cellular Therapy(ASTCT)part-Accepted 9January 2023nered with its Transplant Infectious Disease Special Interest Group (TID-SIG)to update its 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation(HCT).A completely new approach wasKey Words.taken with the goal of better serving dinical providers by publishing each standalone topic in the infectious dis-CandidaInvasive candidiasisease series as a concise format of frequently asked questions (FAQ),tables,and figures.Adult and pediatric infec-Guidelinestious disease and HCT content experts developed and then answered FAQs and finalized topics with harmonizedEpidemiologyrecommendations made by assigning an A through E strength of recommendation paired with a level of support-Diagnosising evidence graded I through IIL.This sixth guideline in the series focuses on invasive candidiasis (IC)with FAQsTreatmentto address epidemiology.clinical diagnosis,prophylaxis,and treatment of IC,plus special considerations for pedi-Prophylaxisatric,cord blood,haploidentical,and T cell-depleted HCT recipients and chimeric antigen receptor T cell recipients.Hematopoletic cellas well as future research directions.transplantation2023 The American Society for Transplantation and Cellular Therapy.Published by Elsevier Inc.This is an openaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)INIRODUCTIONreceiving cellular therapies,such as chimeric antigen receptorConditioning chemotherapy-induced mucositis and gastro-(CAR)T cells,at least until neutrophil recovery and in theintestinal graft-versus-host disease (GVHD)represent theabsence of prolonged glucocorticoid therapy.major risk factors for invasive candidiasis (IC)in hematopoieticIn this update to th
